Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

Launched by JIANGSU VCARE PHARMACEUTICAL TECHNOLOGY CO., LTD · Aug 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a medication called Vicagrel for patients with Acute Coronary Syndrome (ACS) who are about to undergo a procedure called Percutaneous Coronary Intervention (PCI). Essentially, this trial is looking at whether taking Vicagrel over a longer period can help patients with ACS recover better after their procedure. The study is currently recruiting participants aged 18 to 80, regardless of gender, who have been diagnosed with ACS and are scheduled for PCI.

Participants in the trial will need to give their consent to join and will be asked to attend follow-up visits as outlined in the study. It's important to note that people with certain health issues, like severe liver disease or those who are pregnant, cannot participate. If you decide to join this trial, you will be part of a carefully controlled study that aims to provide valuable information about how Vicagrel can help in treating ACS.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients between 18 and 80 years old, with no gender restrictions.
• • Patients diagnosed with ACS and scheduled for PCI, including STEMI and NSTE-ACS (UA/NSTEMI).
• • Voluntarily sign the ICF and be able to follow the visit arrangements specified in the protocol during the trial period.
• Exclusion Criteria:
• • Expected survival time\<12 months;
• • Severe liver dysfunction (non heart disease induced ALT or AST\>3x ULN) and cirrhosis;
• • Pregnant or lactating women, or participants and their partners who plan to become pregnant during the trial period;
• • The researchers determined that other reasons were not suitable for participants in this experiment.